Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jan;42(1):426-30.
doi: 10.1128/JCM.42.1.426-430.2004.

Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil

Ivone L Pires  1 , Marcelo A Soares, Francisco A B Speranza, Solange K Ishii, Maria C G Vieira, Maria I F S Gouvêa, Maria A A M Guimarães, Fátima E de Oliveira, Monica M F Magnanini, Rodrigo M Brindeiro, Amilcar Tanuri
Affiliations

Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil

Ivone L Pires et al. J Clin Microbiol. 2004 Jan.

Abstract

The prevalence of mutations that confer resistance to antiretroviral drugs was examined in 56 drug-naive, human immunodeficiency virus type 1 (HIV-1)-infected individuals from the Army Health Service in Rio de Janeiro, Brazil. No primary protease inhibitor mutations were found, but secondary mutations were observed in 51.2% of the samples. Fourteen percent of the viruses had reverse transcriptase inhibitor-associated mutations. Comparative analysis of protease secondary mutations from four different time periods in drug-naive patients in the city of Rio de Janeiro has indicated constant rates for particular mutations. Changes in CD4 cell counts and HIV viral load over time in subtype B- and non-B-infected drug-naive patients were not significantly different.

PubMed Disclaimer

References

    1. Alaeus, A., K. Lidman, A. Björkman, J. Giesecke, and J. Albert. 1999. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 13:901-907. - PubMed
    1. Alexander, C. S., W. Dong, K. Chan, N. Jahnke, M. V. O'Shaughnessy, T. Mo, M. A. Piaseczny, J. S. Montaner, and P. R. Harringan. 2001. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 15:601-607. - PubMed
    1. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141. - PubMed
    1. Bongertz, V., D. C. Bou-Habib, L. F. Brigido, M. Caseiro, P. J. Chequer, J. C. Couto-Fernandez, P. C. Ferreira, B. Galvao-Castro, D. Greco, M. L. Guimaraes, M. I. Linhares de Carvalho, M. G. Morgado, C. A. Oliveira, S. Osmanov, C. A. Ramos, M. Rossini, E. Sabino, A. Tanuri, and M. Ueda. 2000. HIV-1 diversity in Brazil: genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites. J. Acquir. Immune Defic. Syndr. 23:184-193. - PubMed
    1. Brenner, B., M. A. Wainberg, H. Salomon, D. Rouleau, A. Dascal, B. Spira, R. P. Sekaly, B. Conway, and J. P. Routy. 2000. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Int. J. Antimicrob. Agents 16:429-434. - PubMed

Associated data